Welcome
An introduction to the learning zone with Dr Brett King
Meet expert dermatologist Dr Brett King
Brett King MD, PhD, Associate Professor of Dermatology at Yale School of Medicine, specialises in skin diseases recalcitrant to first-line therapies. Dr King has pioneered the use of Janus kinase (JAK) inhibitors in the treatment of alopecia areata and other skin conditions. Dr King will provide expert insight into the complex condition that is alopecia areata throughout this learning zone. In addition Dr King will provide coverage of key topics from AAD 2023 including a dicussion around patient burden with a focus on paediatric alopecia.
Alopecia areata (AA) is a form of non-scarring hair loss. Physiologically, it is a complex T-cell-mediated autoimmune condition, where hair follicles prematurely skip from the growing anagen phase to the resting telogen phase, resulting in hair loss1. It affects people of all ages, including children and adolescents2.
This Alopecia areata Learning Zone aims to educate healthcare professionals (HCP) on:
- Unmet medical needs for AA, such as more effective treatments suitable for long-term use
- Timely AA management by highlighting the lived burden of AA
- Treatment planning for adult patients with severe AA, by describing the pathophysiology underpinning autoimmunity in AA, and the emerging role of treatment with JAK inhibitors
Short, informative videos complement the written content. Watch Lynn Wilks, a patient with AA, discuss her lived experience of AA, and her honest messages for clinicians for management of this condition.
Alopecia areata
Epidemiology, pathophysiology, and lived burden for patients
Alopecia areata management
Diagnosis, treatment options, and JAK inhibitors
Unmet treatment needs for alopecia areata
Challenges presented by unmet needs and the future alopecia areata management
Alopecia areata podcast series
Join Dr Brittany Craiglow, and expert guests, discuss unmet needs and JAK inhibitors in alopecia areata.
Alopecia areata highlights from AAD 2023
Learn more about key highlights in dermatology, focusing on alopecia areata from the American Academy of Dermatology 2023 Annual Meeting.
Full patient interview with transcript
Click here to watch the full interview of alopecia areata patient, Lynn Wilks
WCD 2023 congress highlights on alopecia areata
Read the latest clinical trial results and treatment updates in alopecia areata with highlights from WCD 2023.
References
- Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019;98:74–85.
- Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257–265.
of interest
are looking at
saved
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, who has reviewed the content only for scientific accuracy. EPG Health received funding from the sponsor in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content.